RT Journal Article
T1 Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism
A1 De la Casa-Fages, Beatriz
A1 Fernández-Eulate, Gorka
A1 Gamez, Josep
A1 Barahona-Hernando, Raúl
A1 Morís, Germán
A1 García-Barcina, María
A1 Infante, Jon
A1 Zulaica, Miren
A1 Fernández-Pelayo, Uxoa
A1 Muñoz-Oreja, Mikel
A1 Urtasun, Miguel
A1 Olaskoaga, Ander
A1 Zelaya, Victoria
A1 Jericó, Ivonne
A1 Saez-Villaverde, Raquel
A1 Catalina, Irene
A1 Sola Vendrell, Emma
A1 Martínez-Sáez, Elena
A1 Pujol, Aurora
A1 Ruiz, Montserrat
A1 Schlüter, Agatha
A1 Spinazzola, Antonella
A1 Muñoz-Blanco, Jose Luis
A1 Holt, Ian
A1 Álvarez, Victoria
A1 López de Munaín, Adolfo
A1 Grandas Pérez, Francisco Javier
AB BackgroundPathogenic variants in the spastic paraplegia type 7 gene cause a complicated hereditary spastic paraplegia phenotype associated with classical features of mitochondrial diseases, including ataxia, progressive external ophthalmoplegia, and deletions of mitochondrial DNA.ObjectivesTo better characterize spastic paraplegia type 7 disease with a clinical, genetic, and functional analysis of a Spanish cohort of spastic paraplegia type 7 patients.MethodsGenetic analysis was performed in patients suspecting hereditary spastic paraplegia and in 1 patient with parkinsonism and Pisa syndrome, through next-generation sequencing, whole-exome sequencing, targeted Sanger sequencing, and multiplex ligation-dependent probe analysis, and blood mitochondrial DNA levels determined by quantitative polymerase chain reaction.ResultsThirty-five patients were found to carry homozygous or compound heterozygous pathogenic variants in the spastic paraplegia type 7 gene. Mean age at onset was 40 years (range, 12–63); 63% of spastic paraplegia type 7 patients were male, and three-quarters of all patients had at least one allele with the c.1529C>T (p.Ala510Val) mutation. Eighty percent of the cohort showed a complicated phenotype, combining ataxia and progressive external ophthalmoplegia (65% and 26%, respectively). Parkinsonism was observed in 21% of cases. Analysis of blood mitochondrial DNA indicated that both patients and carriers of spastic paraplegia type 7 pathogenic variants had markedly lower levels of mitochondrial DNA than control subjects (228 per haploid nuclear DNA vs. 176 vs. 573, respectively; P < 0.001).ConclusionsParkinsonism is a frequent finding in spastic paraplegia type 7 patients. Spastic paraplegia type 7 pathogenic variants impair mitochondrial DNA homeostasis irrespective of the number of mutant alleles, type of variant, and patient or carrier status. Thus, spastic paraplegia type 7 supports mitochondrial DNA maintenance, and variants in the gene may cause parkinsonism owing to mitochondrial DNA abnormalities. Moreover, mitochondrial DNA blood analysis could be a useful biomarker to detect at risk families.
PB Wiley
SN 1547-1561
YR 2019
FD 2019
LK https://hdl.handle.net/20.500.14352/100492
UL https://hdl.handle.net/20.500.14352/100492
LA eng
NO De la Casa-Fages, B., Fernández-Eulate, G., Gamez, J., Barahona-Hernando, R., Morís, G., García-Barcina, M., Infante, J., Zulaica, M., Fernández-Pelayo, U., Muñoz-Oreja, M., Urtasun, M., Olaskoaga, A., Zelaya, V., Jericó, I., Saez-Villaverde, R., Catalina, I., Sola, E., Martínez-Sáez, E., Pujol, A., Ruiz, M., Schlüter, A., Spinazzola, A., Muñoz-Blanco, J.L., Grandas, F., Holt, I., Álvarez, V. and López de Munaín, A. (2019), Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism. Mov Disord, 34: 1547-1561. https://doi.org/10.1002/mds.27812
NO Hesperia Foundation
NO Eusko Jaurlaritza
DS Docta Complutense
RD 20 abr 2025